Sep 2, 2016
Ranomics closes US$1.2 million seed round to enhance genetic testing
Ranomics, a Toronto based genomics company today announces the close of a $1.2 million seed round. Ranomics conducts proprietary research aimed at resolving variants of unknown significance (VUS) in genetic testing results. The close of the seed round will scale the company’s research and development, operations and will support global sales targets. In April 2016, the company launched Ranomics RING-Domain, a database of internally conducted high-throughput functional studies of 2,000 potential mutations of BRCA1, one of the most commonly mutated genes in breast and ovarian cancers.
Aug 5, 2016
Ranomics Establishes Business Operations at Johnson & Johnson Innovation, JLABS Toronto
Ranomics is now a select member of Johnson & Johnson Innovation, JLABS. JLABS are Johnson & Johnson’s external research and development engine, providing a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. JLABS Toronto is affiliated with Johnson & Johnson Innovation, The University of Toronto, MaRS Discovery District, Janssen Inc., MarS Innovation, and the Government of Ontario. Ranomics will now conduct its business operations at Toronto JLABS (101 College St.
Aug 3, 2016
Ranomics Partners with Castle Medical to classify VUS in Clinical Tests
Castle Medical, a genetic testing company located in Atlanta, Georgia, has partnered with Ranomics to use its functional studies data to classify Variants of Unknown Significance in genetic tests for the BRCA1 gene. Following the American College of Medical Genetics (ACMG) guidelines for the interpretation of sequence variants, and in combination with its multiple gene sequencing platforms, Castle Medical plans to leverage Ranomics’ database to classify variants in genes that predispose patients to hereditary breast cancer.
Jun 2, 2016
Ranomics Partners With Beijing Genomics Institute (BGI) To Classify Variants of Unknown Significance
BGI, global leader in genomics research and clinical applications, is actively using functional studies data provided by biotech startup, Ranomics, for gene variant classification. Ranomics’ database offers experimental data about genetic Variants of Unknown Significance (VUS), providing new insights into the function of VUS in model organisms. Following the American College of Medical Genetics (ACMG) guidelines for the interpretation of sequence variants, and in combination with its multiple gene sequencing platforms, BGI plans to leverage Ranomics’ database to classify variants of susceptibility genes in Chinese high-risk breast cancer patients.
May 25, 2016
Veritas Genetics Partners with Pioneer Ranomics to Classify Variants of Uncertain Significance
We are pleased to announce that we are working with Veritas Genetics, the first company to offer $999 whole genome sequencing, to enhance BRCA1 variant classification in hereditary cancer genetic testing.
Apr 18, 2016
Product Launch: Ranomics BRCA1 RING-Domain Variant Database
Ranomics, a Toronto based biotech startup with a mission to resolve Variants of Unknown Significance (VUS) in genetic testing results, launches Ranomics RING-Domain today. Ranomics RING domain is a first-in-class database of functional studies for 2,000 variants of BRCA1, a commonly mutated gene in hereditary breast and ovarian cancers. The database will hugely impact VUS resolution and variant classification efforts in the genomics industry, as approximately sixty percent of all genetic tests for hereditary cancers identify a VUS, which can lead to inconclusive test results and severely impair patient care.
Apr 14, 2016
Ranomics Concludes Successful Pilot Project with Veritas Genetics
Ranomics has recently concluded a successful variant classification project with Massachusetts-based genetic testing company, Veritas Genetics. In this study, Ranomics conducted conclusive functional studies of BRCA1 variants provided by Veritas and greatly assisted their variant classification efforts. This pilot study demonstrated the strength and reliability of functional studies in genetic variant classification as a complement to software algorithms and family based studies. Veritas is one of the first clinical laboratories to implement Ranomics’ functional data as part of their variant classification process.
Apr 1, 2016
Ranomics Announces Partnership with Interactive Biosoftware
Ranomics announces partnership with Interactive Biosoftware, a software company based in France that specializes in genetic variant annotation and reporting. Starting in June 2016, users of Interactive Biosoftware will have access to Ranomics’ functional data through the Alamut Visual software platform connected to Ranomics API, with the option of choosing between Ranomics’ Standard or Premium subscription packages.
Mar 14, 2016
Ranomics Scientific Advisory Board members, Dr. Song Sun and Dr. Frederick Roth, and CEO Cathy Tie, co-author manuscript published in Genome Research
An extended set of yeast-based functional assays accurately identifies human disease mutations. Link to Manuscript
Aug 20, 2015
Ranomics Announces Leading Genetic Testing Experts to Join Advisory Board
We are excited to announce that Mat Falkowski, the founder of Invitae, and Brian Naughton, the founding scientist of 23andMe, will be joining the Ranomics advisory board. The advisory board will work alongside the Ranomics’ leadership team on strategic planning for the business.
Jun 11, 2015
Ranomics launches at Indie Bio's First Demo Day
Feb 28, 2015
Ranomics receive funding from Indie Bio accelerator in San Francisco, California